Kümmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D.N, Kisala M, Burri C, Blesson S, Valverde Mordt O. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. PLoS Negl Trop Dis. 2021;15(11):e0009903. DOI: 10.1371/journal.pntd.0009903

2021
Journal Article
PubMed (34748572)
Link

Mesu V.K.B.K, Mutombo Kalonji W, Bardonneau C, Valverde Mordt O, Ngolo Tete D, Blesson S, Simon F, Delhomme S, Bernhard S, Mahenzi Mbembo H, Mpia Moke C, Lumeya Vuvu S, Mudji E'kitiak J, Akwaso Masa F, Mukendi Ilunga M, Mpoyi Muamba Nzambi D, Mayala Malu T, Kapongo Tshilumbwa S, Botalema Bolengi F, Nkieri Matsho M, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021;9(7):e999-e1008. DOI: 10.1016/s2214-109x(21)00208-4

2021
Journal Article
PubMed (34143998)
Link

Mesu V.K.B.K, Kalonji W.M, Bardonneau C, Mordt O.V, Blesson S, Simon F, Delhomme S, Bernhard S, Kuziena W, Lubaki J.F, Vuvu S.L, Ngima P.N, Mbembo H.M, Ilunga M, Bonama A.K, Heradi J.A, Solomo J.L.L, Mandula G, Badibabi L.K, Dama F.R, Lukula P.K, Tete D.N, Lumbala C, Scherrer B, Strub-Wourgaft N, Tarral A. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144-154. DOI: 10.1016/S0140-6736(17)32758-7

2018
Journal Article
PubMed (29113731)

Burri C, Yeramian P.D, Allen J.L, Merolle A, Serge K.K, Mpanya A, Lutumba P, Mesu V.K, Bilenge C.M, Lubaki J.P, Mpoto A.M, Thompson M, Munungu B.F, Manuel F, Josenando T, Bernhard S.C, Olson C.A, Blum J, Tidwell R.R, Pohlig G. Efficacy, safety, and dose of pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies. PLoS Negl Trop Dis. 2016;10(2):e0004362. DOI: 10.1371/journal.pntd.0004362

2016
Journal Article
PubMed (26881924)
Link

Mordt O.V, Bernhard S, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Tete D, Nganzobo P, Mubwa N, Blésson S, Tarral A, Wourgaft N.S. Nifurtimox eflornithine combination therapy phase IIIb field trial (NECT Field): final effectiveness and safety results. Trop Med Int Health, 2015;20(Suppl. 1):325. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland

2015
Conference Paper

Mordt O.V, Bernhard S, Ghabri S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Tete D, Nganzobo P, Mubwa N, Blésson S, Tarral A. NECT feld phase IIIb trial: final effectiveness in adults and children results. Trop Med Int Health, 2013;18(Suppl. 1):59-60

2013
Conference Paper